Drugs & Aging

, Volume 19, Issue 12, pp 891–898 | Cite as

Defining the Role of the Caregiver in Alzheimer’s Disease Treatment

  • Henry Brodaty
  • Alisa Green
Leading Article


The day-to-day responsibility of caring for a person with dementia often exacts a toll upon the caregiver, which may be manifested psychologically, physically, socially and financially.

The last decade has witnessed the advent of drug availability for the treatment of Alzheimer’s disease, specifically the cholinesterase inhibitors. Caregivers are integral to the initiation, administration and monitoring of treatment. In particular, they provide substitute informed consent when patients are no longer competent to do so. While there is evidence that cholinesterase inhibitors may reduce caregiver burden and time spent assisting patients, there are also burdens associated with being the person responsible for administering medication.

Caregivers are key to research into the use of medications for Alzheimer’s disease. They have roles in recruitment and consent and monitoring response and adverse effects. Increasingly, caregivers themselves are recognised as legitimate targets for evaluating the efficacy of new pharmacological agents for Alzheimer’s disease (as benefits have been demonstrated for them).

Caregivers have responsibilities regarding the drug treatment of patients with Alzheimer’s disease, and require information about the medications so that they can have realistic expectations. Doctors need to work in partnership with care-givers and patients when prescribing drugs for Alzheimer’s disease.


  1. 1.
    Barer BM, Johnson CL. A critique of the caregiving literature. Gerontologist 1990; 30(1): 26–9PubMedCrossRefGoogle Scholar
  2. 2.
    Consumer Health Sciences. Princeton (NJ): LLC, Dec 1999. Alzheimer’s caregiver project methodology [online]. Available at URL: http://www.chsinternational.com/methodology_alzheimers_caregiver_project.asp Google Scholar
  3. 3.
    Brodaty H, Hadzi-Pavlovic D. Psychosocial effects on care-givers of living with persons with dementia. Aust N Z J Psychiatry 1990; 24: 351–61PubMedCrossRefGoogle Scholar
  4. 4.
    Baumgarten M, Battista RN, Infante-Rivard C, et al. The psychological and physical health of family members caring for an elderly person with dementia. J Clin Epidemiol 1992; 45(1): 61–70PubMedCrossRefGoogle Scholar
  5. 5.
    Grafström M, Winblad B. Family burden in the care of the demented and nondemented elderly — a longitudinal study. Alzheimer Dis Assoc Disord 1995; 9(2): 78–86PubMedCrossRefGoogle Scholar
  6. 6.
    Gonzalez-Salvador MT, Arango C, Lyketsos CG, et al. The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry 1999; 14(9): 701–10PubMedCrossRefGoogle Scholar
  7. 7.
    Wright LK, Hickey JV, Buckwalter KC, et al. Emotional and physical health of spouse caregivers of persons with Alzheimer’s disease and stroke. J Adv Nurs 1999; 30: 552–63PubMedCrossRefGoogle Scholar
  8. 8.
    Stephens MA, Ogrocki PK, Kinney JM. Sources of stress for family caregivers of institutionalized patients. J Appl Gerontol 1991; 10(3): 328–42PubMedCrossRefGoogle Scholar
  9. 9.
    Schulz R, Vistainer P, Williamson GM. Psychiatric and physical morbidity effects of caregiving. J Gerontol 1990; 45: P181–91PubMedCrossRefGoogle Scholar
  10. 10.
    Haley WE, Levine EG, Brown SL, et al. Stress, appraisal, coping and social support as predictors of adaptational outcome among dementia caregivers. Psychol Aging 1987; 2: 323–30PubMedCrossRefGoogle Scholar
  11. 11.
    Schulz R, Williamson GM. The measurement of caregiver outcomes in Alzheimer disease research. Alzheimer Dis Assoc Disord 1997; 11(6): 117–24PubMedGoogle Scholar
  12. 12.
    Brodaty H. The family and drug treatments for Alzheimer’s disease. In: Gauthier S, editor. Pharmacotherapy of Alzheimer’s disease. London: Martin Dunitz, 1998: 123–39Google Scholar
  13. 13.
    Braekhus A, Oksengard AR, Engedal K, et al. Social and depressive stress suffered by spouses of patients with mild dementia. Scand J Prim Health Care 1998; 16: 242–6PubMedGoogle Scholar
  14. 14.
    Max W. Cost of illness of dementia. In: Health economics of dementia. Chichester: Wiley, 1998: 197–206Google Scholar
  15. 15.
    Leon J, Neumann PJ, Hermann RC, et al. Health-related quality-of-life and service utilization in Alzheimer’s disease: a cross sectional study. Am J Alzheimers Dis 2000; 15(2): 94–108CrossRefGoogle Scholar
  16. 16.
    Max W, Webber PA, Fox PJ. Alzheimer’s disease: the unpaid burden of caring. J Aging Health 1995; 7: 179–99PubMedCrossRefGoogle Scholar
  17. 17.
    Mace NK, Rabins PV. The 36-hour day. Baltimore (MD): Johns Hopkins University Press, 1991Google Scholar
  18. 18.
    Langa KM, Chernew ME, Kabeto MU, et al. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J Gen Intern Med 2001; 16: 770–8PubMedCrossRefGoogle Scholar
  19. 19.
    Brodaty H, McGilchrist C, Harris L, et al. Time until institutionalization and death in patients with dementia: role of care-giver training and risk factors. Arch Neurol 1993; 50: 643–50PubMedCrossRefGoogle Scholar
  20. 20.
    Morycz RK. Caregiving strain and the desire to institutionalise family members with Alzheimer’s disease. Res Aging 1985; 7: 329–61PubMedCrossRefGoogle Scholar
  21. 21.
    Annerstedt L, Elmstahl S, Ingvad B, et al. Family caregiving in dementia — an analysis of the caregiver’s burden and the “breaking-point” when home care becomes inadequate. Scand J Public Health 2000; 28: 23–31PubMedGoogle Scholar
  22. 22.
    Waite LM, Broe GA, Grayson DA, et al. The incidence of dementia in an Australian community population: the Sydney Older Persons Study. Int J Geriatr Psychiatry 2001; 16: 680–9PubMedCrossRefGoogle Scholar
  23. 23.
    Alafuzoff, I Soininen, H. Neuropathology and ethiopathogenesis of Alzheimer’s disease. In: Qizilbash N, Schneider L, Chui H, et al., editors. Evidence-based dementia practice. Oxford: Blackwell, 2002: 244–59Google Scholar
  24. 24.
    Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66: 137–47PubMedCrossRefGoogle Scholar
  25. 25.
    Cummings J. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 157: 4–15PubMedGoogle Scholar
  26. 26.
    Qizilbash N, Birks J, Lopez Arrieta J, et al. Tacrine for Alzheimer’s disease (Cochrane Review). Available in the Cochr-ane Library. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Oxford Update Software, 2001Google Scholar
  27. 27.
    Winblad B, Engedal MD, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489–95PubMedCrossRefGoogle Scholar
  28. 28.
    Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998; 50: 136–45PubMedCrossRefGoogle Scholar
  29. 29.
    Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer’s disease-results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237–44PubMedCrossRefGoogle Scholar
  30. 30.
    Mohs R, Doody R, Morris JL, et al. Donepezil preserves functional status in Alzheimer’s disease patients: results from a 1-year prospective placebo-controlled study. Eur Neuro-psychopharmacol 1999; 9 Suppl. 5: S328CrossRefGoogle Scholar
  31. 31.
    Doody RS. Clinical profile of donepezil in the treatment of Alzheimer’s disease. Gerontology 1999; 45 Suppl. 1: 23–32PubMedCrossRefGoogle Scholar
  32. 32.
    Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613–20PubMedCrossRefGoogle Scholar
  33. 33.
    Farlow M, Anand R, Messina J, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur Neurol 2000; 44: 236–41PubMedCrossRefGoogle Scholar
  34. 34.
    Birks JS, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer’s disease (Cochrane review). Available in the Cochrane Library. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Oxford Update Software, 2001Google Scholar
  35. 35.
    McKeith IG, Grace JB, Walker Z, et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 2000; 15: 387–92PubMedCrossRefGoogle Scholar
  36. 36.
    Olin J, Schneider L. Systematic review of galantamine for Alzheimer’s disease (Cochrane review). Available in the Cochrane Library. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Oxford Update Software, 2001Google Scholar
  37. 37.
    Zajaczkowski W, Quack G, Danysz W. Infusion of (+)-MK-801 and metamine — contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 1996; 296: 239–46PubMedCrossRefGoogle Scholar
  38. 38.
    Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best study. Int J Geriatr Psychiatry 1999; 14(2): 135–46PubMedCrossRefGoogle Scholar
  39. 39.
    Reisberg B, Windscheif U, Ferris SH, et al. Memantine in moderately severe to severe Alzheimer’s disease (AD): results of a placebo-controlled 6-month trial [abstract]. Neurobiol Aging 2000; 21(1S): S275CrossRefGoogle Scholar
  40. 40.
    Orgogozo JM, Rigaud AS, Stöffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33: 1834–9PubMedCrossRefGoogle Scholar
  41. 41.
    Wilcock G, for the MMM 500 trial group. Cognitive improvement my memantine in a placebo-controlled trial in mild to moderate vascular dementia (the MMM 500 trial) [online]. Poster presented at the 6th International Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5–8; Stockholm, Sweden. Available at URL: http://www.memant-ine.com/inhalte/s1.html
  42. 42.
    Tariot PN, Blazina L. The psychopathology of dementia. In: Morris JC, editor. Handbook of dementing illnesses. New York: Marcel Dekker, 1994: 461–75Google Scholar
  43. 43.
    Peisah C, Brodaty H. Pharmacological management of challenging behaviours in people with dementia. Geriatric Therapeutics 1997; 27(1): 49–57Google Scholar
  44. 44.
    Fillit HM, Gutterman EM, Brooks RL. Impact of donepezil on caregiving burden for patients with Alzheimer’s disease. Int Psychogeriatr 2000; 12(3): 389–401PubMedCrossRefGoogle Scholar
  45. 45.
    Shikiar R, Shakespeare A, Sagnier P-P, et al. The impact of metrifonate therapy on caregivers of patients with Alzheimer’s disease: results from the MALT clinical trial. J Am Geriatr Soc 2000; 48: 268–74PubMedGoogle Scholar
  46. 46.
    Tariot PN, Truyen L. Galantamine reduces the distress of caregivers of Alzheiimer’s disease patients [abstract]. Proceedings of the 10th Congress of the International Psycho-geriatrics Association (IPA); 2001 Sep 9–14; Nice, France. Int Psychogeriatr 2001; 13(S2): P348Google Scholar
  47. 47.
    Mastey V, Wimo A, Winblad B, et al. Donepezil reduces the time caregivers spend providing care: results of a one-year, double-blind, randomized trial in patients with mild to moderate Alzheimer’s disease [abstract]. J Am Geriatr Soc 2001; 49(4): S20Google Scholar
  48. 48.
    Lilienfeld S, Gaens E. Galantamine alleviates caregiver burden in Alzheimer’s disease: a 12 month study. Poster presented at the 5th Congress of the European Federation of Neurological Societies; 2000 Oct 14–18: Copenhagen, Denmark. Eur J Neurol 2000; 7 (Suppl. 3): P3111Google Scholar
  49. 49.
    Clipp EC, Moore MJ. Caregiver time use: an outcome measure in clinical trial research on Alzheimer’s disease. Clin Pharmacol Ther 1995; 58(2): 228–36PubMedCrossRefGoogle Scholar
  50. 50.
    Hinchliffe A, Katona C, Livingstone G. The assessment and management of behavioural manifestations of dementia: a review and results of a controlled trial. International Journal of Psychiatry in Clinical Practice 1997; 1(13): 157–68CrossRefGoogle Scholar
  51. 51.
    Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Tacrine Study Group. Neurology 1996; 47(1): 166–77PubMedCrossRefGoogle Scholar
  52. 52.
    McRae T, Knopman D, Duttagupta S, et al. Donepezil delays time to nursing home placement [abstract]. J Am Geriatr Soc 2001; 49(4): S132Google Scholar
  53. 53.
    Brodaty H, Grossman F, Bruynseels J, et al. Risperidone in the treatment of agitation and psychosis of dementia. Proceedings of the 10th Congress of the International Psychogeriatrics Association; 2001 Sep 9–14: Nice, France. Int Psychogeriatr 2001; 13(S2): S108Google Scholar
  54. 54.
    Ranelli PL, Aversa SL. Medication-related stressors among family caregivers. Am J Hosp Pharm 1994; 51(1): 75–9PubMedGoogle Scholar
  55. 55.
    Green A, Brodaty H. Care-giver interventions. In: Qizilbash N, Schneider L, Chui H, et al., editors. Evidence-based dementia practice. Oxford: Blackwell Publishing, 2002: 764–94Google Scholar
  56. 56.
    Brodaty H, Green A, Koschera A. Evidence bases for interventions for caregivers of people with dementia [abstract]. J Neurol Sci 2001; 187 Suppl. 1: S118Google Scholar
  57. 57.
    Rockwood K, MacKnight C. Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials. Neuroepidemiology 2001; 20(2): 51–6PubMedCrossRefGoogle Scholar
  58. 58.
    Bent S, Saint S, Vittinghoff E, et al. Antibiotics in acute bronchitis: a meta-analysis. Am J Med 1999; 107(1): 62–7PubMedCrossRefGoogle Scholar
  59. 59.
    Brodaty H, Gresham M. Effect of a training programme to reduce stress in caregivers of patients with dementia. BMJ 1989; 299: 1375–9PubMedCrossRefGoogle Scholar
  60. 60.
    Brodaty H, Gresham M, Luscombe G. The Prince Henry Hospital Dementia Caregivers’ Training Programme. Int J Geriatr Psychiatry 1997; 12: 183–92PubMedCrossRefGoogle Scholar
  61. 61.
    Mittelman MS, Ferris SH, Steinberg G, et al. An intervention that delays institutionalisation of Alzheimer’s disease patients: treatment of spouse-caregivers. Gerontologist 1993; 33(6): 730–40PubMedCrossRefGoogle Scholar
  62. 62.
    Mittelman MS, Ferris SH, Shulman E, et al. A comprehensive support group program: effect on depression in spouse-caregivers of AD patients. Gerontologist 1995; 35: 792–802PubMedCrossRefGoogle Scholar
  63. 63.
    Mittelman MS, Ferris SH, Shulman E, et al. A family intervention to delay nursing home placements of patients with Alzheimer’s disease: a randomized controlled trial. JAMA 1996; 276(21): 1725–31PubMedCrossRefGoogle Scholar
  64. 64.
    Mittelman MS, Brodaty H, Burns A. A multinational clinical trial of the effectiveness of a combined psychosocial and pharmacological intervention for AD patients and family caregivers. Proceedings of the World Alzheimer Congress; 2000 July 9–13; Washington (DC)Google Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Henry Brodaty
    • 1
    • 2
  • Alisa Green
    • 1
  1. 1.Academic Department for Old Age PsychiatryPrince of Wales HospitalRandwickAustralia
  2. 2.School of PsychiatryUniversity of New South WalesSydneyAustralia
  3. 3.Academic Department for Old Age Psychiatry, The Euroa CentrePrince of Wales HospitalRandwickAustralia

Personalised recommendations